New Drug Application Completed for Larotrectinib for Solid Tumors Harboring NTRK Gene…
The new drug application (NDA) for larotrectinib (LOXO-101) for treatment of patients with locally advanced or metastatic solid tumors that habor an NTRK gene fusion has been completed.
Read full article (External website)
Leave a Reply
Want to join the discussion?Feel free to contribute!